Summary
Antibodies against hepatitis C (HCV) in 512 patients were measured by an enzyme immunoassay (Ortho-HCV ELISA). The frequency of antiHCV was 80%, 86%, 85% in nonB (NB) chronic hepatitis (CH), cirrhosis (LC), hepatocellular carcinoma (HCC), respectively; 70%, 90% in alcoholic (AL) LC, HCC; 15%, 33%, 58% in hepatitis B (HB) CH, LC, HCC, respectively. Anti-HCV positive cirrhotics had a shorter survival time and earlier development of HCC than anti-HCV negative cirrhotics. The fndings suggest that HCV is a major cause of NB chronic liver diseases and may play a pathogenetic role in AL and HB liver diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Choo QL, Kuo G, Weiner AJ, et al: Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:352–362
Kuo G, Choo QL, Alter HJ, et al: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989:244:362–364
Hopf U, Möller B, Kuther D, et al: Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatology 1990;10:69–76
Bruix J, Barrera JM, Calvet X, et al: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 1004–1006
Di Bisceglie AM, Martin P, Kassisandes C, et al: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J med 1989;321: 1506–1510
Davis GL, Baiart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled trial. N Engl J Med 1989:321:1501–1506
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yoshikawa, M., Tsujii, T., Fukui, H. et al. Hepatitis C virus infection in patients with chronic liver diseases. Gastroenterol Jpn 26 (Suppl 3), 202–205 (1991). https://doi.org/10.1007/BF02779299
Issue Date:
DOI: https://doi.org/10.1007/BF02779299